Published on 24/12/2025
Accelerating Rare Disease Therapies Through Fast Track and Breakthrough Designations
The Need for Expedited Development in Rare Diseases
Rare diseases—often debilitating, progressive, and life-threatening—affect millions worldwide, yet most lack approved treatments. Traditional drug development timelines spanning 10–15 years are incompatible with the urgent needs of rare disease patients. Recognizing this, regulatory agencies like the U.S. Food and Drug Administration (FDA) have developed expedited pathways to speed up access to safe and effective therapies for serious and life-threatening conditions with unmet medical need.
Two of the most impactful tools in this regulatory toolkit are Fast Track Designation and Breakthrough Therapy Designation. Both offer significant benefits to developers of rare disease therapies—especially when combined with Orphan Drug Designation, Accelerated Approval, or Priority Review.
Fast Track Designation: Overview and Eligibility
Fast Track is a formal FDA program designed to facilitate the development and expedite the review of drugs that treat serious conditions and address unmet medical needs.
Eligibility Criteria:
- The drug must treat a serious or life-threatening condition (e.g., Duchenne muscular dystrophy, cystic fibrosis, Batten disease)
- There must be no existing therapy, or the drug must show advantages over available treatments
Key Benefits:
- More frequent meetings and written communication with the FDA
- Rolling
Example: A sponsor developing a gene therapy for Leber congenital amaurosis received Fast Track designation based on early data showing significant vision improvement compared to supportive care.
Breakthrough Therapy Designation: Overview and Criteria
Breakthrough Therapy Designation (BTD) is an even more selective FDA program intended for drugs that may offer substantial improvement over existing therapies on one or more clinically significant endpoints.
Eligibility Criteria:
- Preliminary clinical evidence must demonstrate substantial improvement over available therapy
- Applies to serious or life-threatening conditions
Key Benefits:
- All Fast Track features
- Intensive FDA guidance on efficient drug development
- Organizational commitment from FDA senior managers
- Eligibility for rolling review and other expedited pathways
Example: Exondys 51 (eteplirsen) for Duchenne muscular dystrophy received BTD after early clinical evidence showed dystrophin expression—a surrogate endpoint associated with slowed disease progression.
Key Differences: Fast Track vs Breakthrough Therapy
While both programs offer expedited pathways, they differ primarily in the strength of evidence required and level of FDA engagement:
| Feature | Fast Track | Breakthrough Therapy |
|---|---|---|
| Initial Evidence Required | Nonclinical or early clinical data | Preliminary clinical evidence of substantial improvement |
| FDA Support Level | Frequent interactions | Intensive guidance, senior management involvement |
| Rolling Review | Yes | Yes |
| Accelerated Approval Eligibility | Yes | Yes |
Both designations can be requested at the IND stage or anytime during clinical development. Sponsors are encouraged to submit robust data packages and justify the designation criteria in their request letters.
Regulatory Submission and Review Process
Once granted, Fast Track and Breakthrough Therapy designations unlock a more flexible, responsive, and efficient regulatory dialogue. Typical milestones include:
- Type B meetings with FDA to align on trial design and endpoints
- Protocol Agreement letters under Special Protocol Assessment (SPA)
- Rolling NDA/BLA submissions, allowing early modules to be reviewed in advance
- Post-marketing study expectations clarified early in development
Proactive engagement with the FDA significantly reduces the risk of costly missteps, such as inadequate trial powering or suboptimal endpoint selection.
Benefits for Rare Disease Developers
Fast Track and Breakthrough Therapy designations are particularly valuable in the rare disease landscape because:
- Clinical trials in rare diseases often rely on small sample sizes or surrogate endpoints
- There are frequently no established therapies to serve as comparators
- Regulatory flexibility and speed are vital for conditions with early mortality or severe morbidity
By receiving these designations, sponsors gain credibility with investors, attract partnerships, and build momentum for rare disease programs that would otherwise struggle to reach commercialization.
Combining with Other Rare Disease Incentives
Expedited designations are most powerful when combined with other incentives such as:
- Orphan Drug Designation: Grants 7 years (US) or 10 years (EU) of market exclusivity
- Rare Pediatric Disease Priority Review Vouchers (PRVs): Transferable and potentially worth over $100 million
- Accelerated Approval: Approval based on surrogate endpoints with post-marketing requirements
Case in point: A treatment for CLN2 disease received orphan, breakthrough, and priority review designations—leading to marketing approval within 4 years of first-in-human dosing.
Global Perspectives: EMA’s PRIME vs FDA’s Programs
The European Medicines Agency (EMA) offers similar expedited pathways through its PRIME (PRIority MEdicines) scheme. While not identical to Fast Track or Breakthrough Therapy, PRIME provides:
- Early scientific advice and dialogue
- Dedicated contact points
- Eligibility for accelerated assessment
Sponsors developing therapies for rare diseases may benefit from parallel applications with both the FDA and EMA to ensure harmonized development strategies across regions.
Best Practices for Sponsors Seeking Expedited Designations
To improve the likelihood of receiving Fast Track or Breakthrough Therapy status:
- Engage FDA early through pre-IND or INTERACT meetings
- Submit robust, data-driven designation request letters
- Clearly articulate how the therapy addresses unmet need or improves clinical outcomes
- Prepare supporting material such as investigator brochures, preliminary datasets, and comparison to current standard of care
Use real-world evidence (RWE), natural history studies, and patient-reported outcomes (PROs) to strengthen your submission—especially in ultra-rare populations.
Conclusion: Empowering Rare Disease Innovation Through Expedited Pathways
Fast Track and Breakthrough Therapy designations are transformative tools for rare disease developers. They not only accelerate timelines and regulatory interactions but also signal therapeutic potential to the broader scientific and investment communities. When used strategically and ethically, these designations reduce the time between discovery and patient access—helping bring hope to those with the greatest need.